Rapid integration site mapping

• US 20050233364A1
• Filed: 04/06/2005
• Published: 10/20/2005
• Est. Priority Date: 04/20/2004
• Status: Abandoned Application

• Current Assignee: The United States of America As Represented By The Secretary of Agriculture
• Original Assignee: The United States of America As Represented By The Secretary of Agriculture
• Inventors: Burgess, Shawn, Wu, Xiaolin
• Application Number:
  US11/101,299
• Publication Number:
  US 20050233364A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12N 15/1034 Isolating an individual clone by screening libraries
• CPC Class Codes: C12Q 1/70 involving virus or bacteriophage immunoassay for viruses G01N33/56983

Abstract

High-throughput methods for mapping integration sites resulting from one or more integrations, such as infection by a retrovirus, are disclosed. The disclosed methods require no selection for specific phenotypes such as antibiotic resistance, and thereby may avoid selection bias. Moreover, the linker-based amplification is simple and rapid, and by using a frequently cutting restriction enzyme, the amplicons are small, which significantly decreases possible amplification and cloning biases.

Claims

1. A method of identifying an integrant integration site, comprising:

(a) obtaining a nucleic acid molecule comprising at least one integrant at an integration site and at least one first restriction site (N1 site) cleavable by a first restriction enzyme (N1), wherein the integrant comprises in the following order;

(i) a first terminal repeat, comprising a target end and a terminal repeat-specific primer (TRP) binding site, which can stably bind a TRP,

(ii) at least one second restriction site (N2 site) cleavable by a second restriction enzyme (N2), and

(iii) a second terminal repeat, comprising a non-target end and a sequence, which can stably bind a TRP, and which is in the same orientation as the TRP binding site in the first terminal repeat,

wherein there are no N1 sites or N2 sites in the TRP binding site or between the target end and the TRP binding site, and wherein there are no N1 sites between the N2 site closest to the non-target end and the non-target end;

(b) digesting the nucleic acid molecule with N1 and N2 to yield a population of nucleic acid fragments, wherein at least some of the fragments have at least one N1 end;

(c) ligating an extension-dependent linker to at least some of the N1 ends to produce a population of linkered fragments;

(d) contacting the linkered fragments with the TRP;

(e) extending the TRP to yield at least one extension product having a linker-specific primer (LSP) binding site complementary to a LSP;

(f) amplifying the linkered fragments and extension product(s) with TRPs and LSPs to yield at least one amplification product; and

(g) sequencing at least one amplification product to yield at least one nucleic acid sequence flanking the target end, thereby identifying at least one integrant integration site.

2. The method of claim 1, wherein the integrant is a virus, a transposon, or an integrating gene therapy vector.

3. The method of claim 2, wherein the integrant is a virus.

4. The method of claim 3, wherein the integrant is murine leukemia virus (MLV) or human immunodeficiency virus 1 (HIV-1).

5. The method of claim 1, wherein the TRP binding site is no more than about 200 base pairs from the target end.

6. The method of claim 1, wherein the target end is the 3′

end of the integrant.

7. The method of claim 1, wherein the target end is the 5′

end of the integrant.

8. The method of claim 1, wherein the nucleic acid molecule is genomic DNA.

9. The method of claim 8, wherein the nucleic acid molecule is human genomic DNA.

10. The method of claim 1, wherein N1 is no more than a 5-base cutter.

11. The method of claim 10, wherein N1 is no more than a 4-base cutter.

12. The method of claim 1, wherein N2 cuts the nucleic acid molecule less frequently than does N1.

13. The method of claim 11, wherein N1 is MseI, RsaI, TaqI, Tri1I or RsaI.

14. The method of claim 1, wherein N2 is PstI or EcoRI.

15. The method of claim 1, wherein the population of nucleic acid fragments comprise an average length of no more than about 300 base pairs.

16. The method of claim 15, wherein the average fragment length is no more than about 100 base pairs.

17. The method of claim 1, wherein the nucleic acid molecule is co-digested with N1 and N2.

18. The method of claim 17, wherein N1 and N2 produce incompatible ends.

19. The method of claim 1, wherein the nucleic acid molecule is sequentially digested with N1 and N2.

20. The method of claim 19, wherein N1 and N2 produce compatible ends.

21. The method of claim 19, wherein the nucleic acid molecule is first digested with N1 and then digested with N2.

22. The method of claim 21 further comprising isolating linkered fragments prior to digesting with N2.

23. The method of claim 1, wherein the integrant further comprises at least one N1 site.

24. The method of claim 1, wherein the method is performed in no more than 14 days.

25. The method of claim 1, wherein the method is performed in no more than 7 days.

26. The method of claim 1, wherein the nucleic acid sequence flanking the target end is no more than about 75 base pairs.

27. The method of claim 26, wherein the nucleic acid sequence flanking the target end is no more than about 30 base pairs.

28. The method of claim 1, wherein at least 200 integration sites are identified.

29. The method of claim 28, wherein at least 500 integration sites are identified.

30. A method of determining the risk potential of an integrating gene therapy vector, comprising:

isolating a nucleic acid molecule, comprising at least one integrated integrating gene therapy vector and at least one reference point, from a treated cell

identifying integration sites of the gene therapy vector according to the method of claim 1;

and

mapping integration sites in relation to at least one reference point;

wherein the map of integration sites provides information about the risk potential of the integrating gene therapy vector.

31. The method of claim 30, wherein the treated cells comprise mammalian cells.

32. The method of claim 31, wherein the mammalian cells comprise human cells.

33. The method of claim 32, wherein the human cells are isolated from a subject to whom the treated cells are to be administered.

34. The method of claim 32, wherein the human cells are isolated from a subject to whom the treated cells were administered.

35. The method of claim 34, wherein the treated cells were administered to the subject as a medical treatment.

36. The method of claim 30, wherein the nucleic acid molecule comprises genomic DNA.

37. The method of claim 30, wherein the integrating gene therapy vector comprises all or part of the genome from MLV or HIV-1.

38. The method of claim 36, wherein the reference point comprises actively transcribed regions of the nucleic acid molecule;

or telomeres.

39. The method of claim 38, wherein reference points in actively transcribed regions comprise translation start sites, transcription start sites, midpoints of coding regions, or stop codons.

40. The method of claim 39, wherein the risk potential of the integrating gene therapy vector is relatively high when substantial numbers of integration sites are located near actively transcribed regions of the nucleic acid molecule.

41. The method of claim 39, wherein the risk potential of the integrating gene therapy vector is relatively low when the distribution of integration sites is substantially random in relation to actively transcribed regions of the nucleic acid molecule.

42. The method of claim 30, wherein at least 500 integration sites are mapped.

43. The method of claim 42, wherein at least 750 integration sites are mapped.

44. The method of claim 43, wherein substantially all integration sites are mapped.